Camelon 125 Indications/Uses

When oral therapy is not possible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, CAMELON powder for injection is indicated for i.v. or i.m., use in the following conditions: Abnormality of adrenocorticoid function, for the treatment of: Primary acute and chronic adrenocortical insufficiency: Hydrocortisone and cortisone are preferred as adjunctive replacement therapy because of their significant mineralocorticoid activities. Replacement of sodium and fluids are also required. In some patients, additional mineralocorticoid replacement may also be necessary.
Secondary adrenocorticoid insufficiency: Glucocorticoid replacement is usually sufficient, a mineralocorticoid is not always required.
Allergic disorders: Drug allergy.
Anaphylactic or anaphylactoid reaction (treatment adjunct): Use of glucocorticoids is generally reserved for prolonged reactions or those not responding to other forms of treatment within 1 hour, or situations in which there is a significant risk of relapse.
Angioedema (treatment adjunct).
Acute non-infectious laryngeal oedema.
Seasonal or perennial allergic rhinitis (chronic oracute).
Serum sickness.
Urticarial transfusion reaction.
Collagen disorders: Indicated during an acute exacerbation or as maintenance therapy: Acute rheumatic (or non-rheumatic) carditis.
Systemic dermatomyocytis (polymyocytis): Glucocorticoids may be the treatment of choice in children with this condition.
Systemic lupus erythematosus.
“Giant cell” arthritis.
Complicated bound tissue disease.
Polyarthritis nodosa.
Polychondritis relapse.
Rheumatoid polymyalgia.
Vasculitis.
Dermatologic disorders: Atopic, contact or exfoliative dermatitis.
Herpetiformic bullous dermatitis.
Severe seborrheic dermatitis.
Severe inflammatory dermatitis.
Severe erythema multiforme (Steven-Johnson syndrome).
Mycosis fungoides.
Pemphigus.
Severe psoriasis.
Pemphigoid.
Localized cutaneous sarcoid.
Gastrointestinal disorders: Treatment of inflammatory bowel disease, including ulcerative colitis.
Regional enteritis (Crohn's disease).
Severe celiac disease.
Oral or parenteral administration indicated when systemic therapy is required during a critical period of the disease, long term use is not recommended.
Haematologic disorders: Acquired haemolytic anemia (autoimmune).
Congenital (erythoid) hypoplastic anemia.
Red blood cell anemia (erythroblastopenia).
Secondary thrombocytopenia (in adults).
Idiophatic thrombocytopenia purpura in adults (orally or i.v. only, i.m. administration is contraindicated).
Haemolysis.
Hepatic disease: Alcoholic hepatitis with encelopathy.
Chronic active hepatitis.
Non-alcoholic hepatitis in women.
Subacute hepatic necrosis.
Hypercalcemia associated with neoplasm (or sarcoidosis).
Non-rheumatoid inflammation: Indicated during an acute episode or exacerbation of the following disorders (local injection is preferred when only a few joints or areas are affected).
Acute and subacute bursitis.
Epicondylitis.
Non-specific acute tenosynovitis.
Neoplastic diseases (treatment adjunct): Indicated in conjuction with appropriate specific antineoplastic disease therapy, for the palliative management of the following neoplastic disease therapy and related problems: Acute or chronic lymphocytic leukemia.
Hodgkin's or non-Hodgkin's lymphomas.
Breast cancer.
Prostatic cancer.
Fever caused by severe cancer.
Multiple myeloma.
Nephrotic syndrome: Indicated to induce diuretics or to reduce proteinuria symptoms in idiophatic necrotic syndrome, long-term therapy may be required to prevent frequent relapses.
Neurologic disease: Tuberculosis meningitis (treatment adjunct). Concurrent administration with appropriate antituberculous chemotherapy in patient with subarachnoid block.
Multiple sclerosis, indicated for acute exacerbation treatment.
Neurotrauma: Spinal cord injury.
Ophthalmic disorders: Treatment of chronic or acute allergic and inflammatory ophthalmic condition: Chorioretinitis.
Choroiditis posterior diffusion.
Allergic conjunctivitis (diffuse posterior choroiditis controlled).
Herpes zoster.
Iridocyclitis.
Keratitis not associated with herpes simplex of fungal infection.
Optic neuritis.
Sympathetic ophthalmia.
Diffuse posterior uveitis.
Pericarditis: Used to eliminate inflammation and fever.
Nasal polyps.
Respiratory diseases: Used for prophylaxis and treatment.
Prophylaxis: Given before or during heart surgery if patient has a pre-existing pulmonary disorder and given before, during and after oral, facial or neck surgery to prevent oedema that may inhibit the airway.
Treatment: Bronchial asthma.
Berylliosis.
Loeffler syndrome (eosinophilic pneumonitis or hyper-eosinophil syndrome).
Aspiration pneumonia.
Symptomatic sarcoidosis.
Fulminanting or disseminated pulmonary tuberculosis (treatment adjunct) when used concurrently with appropriate tuberculosis chemotherapy.
Acute and chronic asthma bronchitis.
Non-cardiogenic pulmonary oedema (caused by protamine sensitivity), treatment should be administered by i.v. or i.m. injection.
Airway obstructing hemangioma (children should be administered by i.v. or i.m. injection).
Pneumonia, Pneumocystis carinii associated with AIDS (treatment adjunct).
Pneumocystis pneumonia in patients infected with HIV virus.
Chronic obstructive pulmonary disease (not controlled with theophylline and β-adrenergic agonist).
Status asthmaticus should be given i.v. or i.m. injection.
Rheumatic disorders: Local injections should be applied only if few joints or areas are involved. Indicated as adjunctive therapy during an acute episode or exacerbation of rheumatic disorders: Ankylosing spondylitis.
Psoriatic arthritis.
Rheumatoid arthritis, including arthritis in children (for patients who cannot be treated with aspirin, steroidal anti-inflammatory agents, rest and physical therapy).
Acute gout arthritis.
Post-traumatic osteoarthritis.
Osteoarthritis synovitis.
Acute calcium pyrophosphate deposition disease (pseudogout, articularis condrocalcinosis, synovitis caused by crystal).
Rheumatica polymyalgia.
Reiter's disease.
Shock therapy caused by adrenocortical insufficiency.
Non-suppurative thyroiditis.
Prophylaxis and treatment of organ transplant rejection: Administration concurrently with other immunosuppressant e.g., azathioprine or cyclosporine.
Trichinosis treatment.